MODULATING MULTIPLE DRUG RESISTANCE VIA CO-DELIVERY OF NANOPARTICLE
Abstract
When various mechanisms in cancer causing cells show resistance towards one or many chemotherapeutics, it hinders the efficacy of chemotherapy. This is referred as multidrug resistance. There are several factors that contribute in MDR. This research specifically focuses on modulate resistance towards multiple drugs by co-delivery of the nanoparticle. This research review has highlighted several delivery systems of nanodrug for overcoming the mechanism followed by MDR. This is done by exploiting, evading or neutralizing the pumps of drug efflux. The research essay has specifically discussed five different system categories. These categories are Mdr-1 and survivin-targeting, Docetaxel and siRNA, Paclitaxel and curcumin, Doxorubicin and paclitaxel and Doxorubicin and PSC 833. Based on the overall discussion, a brief summary is provided. Keywords: Drug resistance, nanomedicine, co-delivery, drug delivery.Keywords:
Drug resistance, nanomedicine, co-delivery, drug delivery.DOI
https://doi.org/10.22270/jddt.v7i3.1424References
Chauhan V P, and Jain R K. Strategies for advancing cancer nanomedicine. Nature materials. 2013, 12: 958-962
Kang C, Sun Y, Wang M, and Cheng X. Nanosized camptothecin conjugates for single and combined drug delivery. European Journal of BioMedical Research. 2016, 2: 8-14
Kang C, Sun Y, Zhu J, Li W, Zhang A, Kuang T, et al. Delivery of Nanoparticles for Treatment of Brain Tumor. Current Drug Metabolism. 2016, 17: 745-754
Sun Y, Kang C, Liu F, and Song L. Delivery of Antipsychotics with Nanoparticles. Drug Development Research. 2016, 77: 393-399
Cheng X. Developing organic and inorganic nanomedicine for cancer therapy. Journal of Drug Delivery and Therapeutics. 2017, 7: 1-4
Chow E K-H, and Ho D. Cancer nanomedicine: from drug delivery to imaging. Science translational medicine. 2013, 5: 216rv214-216rv214
Sun Y, Kang C, Zhang A, Liu F, Hu J, Zhong X, et al. Co-delivery of dual-drugs with nanoparticle to overcome multidrug resistance. European Journal of BioMedical Research. 2016, 2: 12-18
Xu X, Ho W, Zhang X, Bertrand N, and Farokhzad O. Cancer nanomedicine: from targeted delivery to combination therapy. Trends in molecular medicine. 2015, 21: 223-232
Nie S. Understanding and overcoming major barriers in cancer nanomedicine. Nanomedicine. 2010, 5: 523-528
Han R, Sun Y, Kang C, Sun H, and Wei W. Amphiphilic dendritic nanomicelle-mediated co-delivery of 5-fluorouracil and doxorubicin for enhanced therapeutic efficacy. Journal of Drug Targeting. 2017, 25: 140-148
Kang C, Qin J, Osei W, and Hu K. Regulation of protein kinase C-epsilon and its age-dependence. Biochemical and Biophysical Research Communications. 2017, 482: 1201-1206
Cheng X, and Lee R J. The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery. Adv Drug Deliv Rev. 2016, 99: 129-137; doi: 10.1016/j.addr.2016.01.022.
Yin Q, Shen J, Chen L, Zhang Z, Gu W, and Li Y. Overcoming multidrug resistance by co-delivery of Mdr-1 and survivin-targeting RNA with reduction-responsible cationic poly (β-amino esters). Biomaterials. 2012, 33: 6495-6506
Chen Y, Bian Y, Sun Y, Kang C, Yu S, Fu T, et al. Identification of 4-aminoquinoline core for the design of new cholinesterase inhibitors. PeerJ. 2016, 4: e2140
Liu F, Sun Y, Kang C, and Zhu H. Pegylated Drug Delivery Systems: From Design to Biomedical Applications. Nano LIFE. 2016, 6: 1642002
Cheng X, Liu Q, Li H, Kang C, Liu Y, Guo T, et al. Lipid Nanoparticles Loaded with an Antisense Oligonucleotide Gapmer Against Bcl-2 for Treatment of Lung Cancer. Pharm Res. 2017, 34: 310-320; doi: 10.1007/s11095-016-2063-5.
Zheng C, Zheng M, Gong P, Deng J, Yi H, Zhang P, et al. Polypeptide cationic micelles mediated co-delivery of docetaxel and siRNA for synergistic tumor therapy. Biomaterials. 2013, 34: 3431-3438
Yang Z, Xie J, Zhu J, Kang C, Chiang C, Wang X, et al. Functional exosome-mimic for delivery of siRNA to cancer: in vitro and in vivo evaluation. Journal of Controlled Release. 2016, 243: 160-171
Yao Z, Sun Y, and Kang C. Structure and Self-Assembly of Multicolored Naphthalene Diimides Semiconductor. Nano LIFE. 2016, 6: 1642007
Zhong X, Sun Y, Kang C, and Wan G. The theory of dielectrophoresis and its applications on medical and materials research. European Journal of BioMedical Research. 2017, 2: 7-11
Qiao H, Fang D, Chen J, Sun Y, Kang C, Di L, et al. Orally delivered polycurcumin responsive to bacterial reduction for targeted therapy of inflammatory bowel disease. Drug Delivery. 2017, 24: 233-242
Song L, Kang C, Sun Y, Huang W, Liu W, and Qian Z. Crocetin Inhibits Lipopolysaccharide-Induced Inflammatory Response in Human Umbilical Vein Endothelial Cells. Cellular Physiology and Biochemistry. 2016, 40: 443-452
Duan Y, Pei K, Cai H, Tu S, Cheng X, Zhang Z, et al. Strategy of integrated evaluation on treatment of traditional Chinese medicine as ‘interaction of system to system’and establishment of novel fuzzy target contribution recognition with herb-pairs, a case study on Astragali Radix-Fructus Corni. Molecular and Cellular Endocrinology. 2016, 434: 219-237
Abouzeid A H, Patel N R, and Torchilin V P. Polyethylene glycol-phosphatidylethanolamine (PEG-PE)/vitamin E micelles for co-delivery of paclitaxel and curcumin to overcome multi-drug resistance in ovarian cancer. International journal of pharmaceutics. 2014, 464: 178-184
Sun Y, and Kang C. Self-Assembly of Peptides into Hydrogel. Journal of Organic & Inorganic Chemistry. 2016,
Sun Y, Kang C, Yao Z, Liu F, and Zhou Y. Peptide-Based Ligand for Active Delivery of Liposomal Doxorubicin. Nano LIFE. 2016, 6: 1642004
Chen Y, Zhang W, Huang Y, Gao F, Sha X, and Fang X. Pluronic-based functional polymeric mixed micelles for co-delivery of doxorubicin and paclitaxel to multidrug resistant tumor. International journal of pharmaceutics. 2015, 488: 44-58
Waller A P, George M, Kalyanasundaram A, Kang C, Periasamy M, Hu K, et al. GLUT12 functions as a basal and insulin-independent glucose transporter in the heart. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2013, 1832: 121-127
XU S-h, Chen K, CHEN M-l, ZHOU P-p, HE G-w, CUI Y-j, et al. Dynamic expression of AQP4 in early stageof ischemia/reperfusion rats and cerebral edema. Chinese Pharmacological Bulletin. 2016: 1433-1441
Xue X, Zhao N-Y, Yu H-T, Sun Y, Kang C, Huang Q-B, et al. Discovery of novel inhibitors disrupting HIF-1α/von Hippel–Lindau interaction through shape-based screening and cascade docking. PeerJ. 2016, 4: e2757
Bajelan E, Haeri A, Vali A M, Ostad S N, and Dadashzadeh S. Co-delivery of doxorubicin and PSC 833 (Valspodar) by stealth nanoliposomes for efficient overcoming of multidrug resistance. Journal of Pharmacy & Pharmaceutical Sciences. 2012, 15: 568-582
Li H, Quan J, Zhang M, Yung B C, Cheng X, Liu Y, et al. Lipid-Albumin Nanoparticles (LAN) for Therapeutic Delivery of Antisense Oligonucleotide against HIF-1alpha. Mol Pharm. 2016, 13: 2555-2562; doi: 10.1021/acs.molpharmaceut.6b00363.
Duan Y, Pei K, Cai H, Tu S, Zhang Z, Cheng X, et al. Bioactivity evaluation-based ultra high-performance liquid chromatography coupled with electrospray ionization tandem quadrupole-time-of-flight mass spectrometry and novel distinction of multi-subchemome compatibility recognition strategy with Astragali Radix-Fructus Corni herb-pair as a case study. Journal of pharmaceutical and biomedical analysis. 2016, 129: 514-534
Li H, Cheng X, Liu Y, Lee Y B, Kim D J, Ahn C-h, et al. Folate receptor-targeted lipid coated albumin nanoparticles (F-LCAN) for therapeutic delivery of RX-0201 (Archexin®), an antisense oligonucleotide against Akt-1. 2016,
Published
Abstract Display: 516 
PDF Downloads: 724 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.